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Abstract 
Extragenital malignant mixed mesodermal müllerian tumors (MT) are rare neoplasms 
with poor prognosis. Most of them affect women older than 60 years. We present here a 
case with primary peritoneal malignant mixed müllerian tumor occurring in a young 
woman who underwent previous hysterectomy and double oophorectomy secondary to 
a benign disease. We report on the clinical, pathological, and immunohistochemical 
features of this lesion, which was composed of a poorly differentiated epithelial 
component and multiple areas of chondromatous differentiation. Along with a brief 
review of previously reported literature about genital and extragenital MT, some 
concepts relevant to this case are discussed. 
 
Introduction 
Malignant mixed müllerian tumors (MT) are a rare mixed mesenchymal and epithelial 
group of neoplasms [1]. Although these tumors occur most commonly in the 
endometrium and less frequently in other parts of the female genital tract, such as the 
cervix, ovaries, fallopian tubes and vagina, extragenital primary peritoneal MT that are 
extremely rare have been described, and only few cases have been reported in the 
literature [1, 2]. These tumors occur commonly in elderly postmenopausal women [1, 2] 
and it has been hypothesized that they arise in the secondary müllerian system consisting 
of the abdominal and pelvic peritoneum and its underlying mesenchymal tissue. They are 
considered neoplasms with a highly aggressive course and very poor prognosis [2].  
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Case Report 
A 46-year-old woman was admitted to the hospital complaining of diffuse abdominal pain and 
swelling, nausea and decrease of appetite. Abdominal examination revealed multiple abdominal masses 
and ascites. She underwent a hysterectomy and oophorectomy 6 years ago, secondary to a benign 
disease; other than this, there was no remarkable gynecological history. 
Abdominal ultrasound and computed tomography revealed multiple peritoneal masses with a 
diameter of 4–10 cm. A vaginal examination was unremarkable. She underwent drainage of the ascites 
and subsequent cytological study revealed adenocarcinoma. Inmunohistochemistry did not help in the 
diagnostic process. An upper digestive endoscopy and colonoscopy were normal. Chest X-ray was 
normal, too. 
Laparotomy achieved total resection of a bleeding abdominal tumor, measuring 10 cm at its maximal 
diameter, attached to the retroperitoneal area, and most of the peritoneal masses leaving approximately 
40% of the visible disease. The postoperative course was difficult. The patient had an Eastern 
Cooperative Oncology Group (ECOG) Performance Status of 3, with diffuse edemas, loss of appetite, 
fatigue and dispnea at moderate physical efforts. After a short course of high doses of steroids such as 
anabolic drugs, intravenous albumin, diuretics, morphine and blood transfusions, the patient achieved 
an ECOG of 1–2 after two weeks and she could leave the hospital. 
Pathologic findings revealed mesenteric tissue diffusely invaded and distorted by a soft tumor. This 
tumor was predominantly solid with areas of hemorrhage. Light microscopy showed a tumor with a 
biphasic pattern. The larger part of the tumor consisted of cords and nests of poorly differentiated 
intermediate-sized cells. Several nuclei displayed a dispersed chromatin pattern. There was a high 
mitotic rate. The tumor was composed of a mixture of carcinomatous and sarcomatous components 
(fig. 1). The carcinoma component was formed by indifferentiated diffuse cells and glandular structures 
composed of larger cells focally resembling adenocarcinoma. The stromal component consisted of 
chondromatous areas (fig. 2), spindle cells with pleomorphic nuclei, mostly with a haphazardous 
architecture, and pleomorphic giant cells in some areas. 
The immunohistochemical findings showed expression of cytokeratins (fig. 3) and smooth muscle 
actin (fig. 4) in the epithelial and mesenchymal components, respectively, and the absence of desmin 
and estrogen and progesterone receptors. 
Postoperatively, the patient was given chemotherapy with a combination of paclitaxel and 
carboplatin in a weekly schedule because of the regular general condition. The patient experienced 
clinical benefit and marked decrease of serum levels of CA 125 after two cycles. At that time, we 
modified the schedule to every 3 weeks. Now, she is well and she continues receiving chemotherapy 6 
months after diagnosis. Computed tomography after 4 cycles revealed partial response. 
Discussion 
MT are uncommon neoplasms characterized by their biphasic pattern containing both 
malignant epithelial and stromal components [1]. These tumors most commonly arise in 
the uterus and other parts of the female genital tract, but the occurrence of MT in an 
extragenital location, although it exists, is very rare. There are different sites for 
extragenital MT and the most frequent location appears to be the pelvic peritoneum. 
Other sites are serosal surface of the colon, retroperitoneum, antero-lateral abdominal 
peritoneum and the mesentery [2]. 
Peritoneal surfaces are a host to a range of benign and malignant diseases commonly 
encountered in the müllerian duct system of the female genital tract [3]. Primary 
peritoneal MT have been thought to arise either from foci of endometriosis, from 
müllerian duct remnants or directly from the mesothelium and submesothelial 
mesenchyme through a process of metaplasia. This müllerian potential of the peritoneal 
serosal and adjacent mesenchyme makes it evident that they share mesodermal ancestry 
with the primary müllerian system, which derives from invaginated coelomic epithelium.  
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Lauchlan called the areas ‘secondary müllerian system’ which are present in the 
peritoneum and not restricted to females [3, 4]. 
In reviews of cases of peritoneal MT, this disease was found to be associated with 
synchronous gynecologic tumors of müllerian duct origin (i.e., ovarian tumors, primary 
serous carcinoma of the peritoneum, fallopian tube cancer, endometrial cancer and cervix 
adenocarcinoma) or colonic carcinomas and serous carcinoma of the peritoneum [5–8]. 
Although this coexistence may be incidental, it may also imply a possible linkage between 
these tumors. Sometimes, these tumors may appear along the clinical evolution of the first 
neoplasm (metachronic) [5]. 
In most cases, MT including genital and extragenital locations are described in 
postmenopausal women older than 60 years who present risk factors such as obesity, 
nulliparity, exogenous estrogen or long-term tamoxifen use [1]. 
Here, we report a case of a young woman with MT stage IIIC of abdominal peritoneum 
origin without other associated tumors. The patient was operated for hysterectomy and 
double oophorectomy 6 years before the diagnosis because of a benign disease; she has no 
other relevant gynecological history and did not present any of the known risk factors for 
this neoplasm. 
The pathologic stage at diagnosis seems to be the most reliable predictor of prognosis 
in MT of uterine origin [3]. Although usually the prognosis of MT is poor, it seems to 
improve with combinations of treatments. Surgical excision is the most effective 
treatment and radiotherapy and various combinations of chemotherapy have achieved 
inconsistent results [9]. However, Wong et al. observed that patients with MT of the 
uterus who received sequential adjuvant therapy, using cisplatin and ifosfamide 
chemotherapy and radiotherapy, had an improved survival rate [10]. 
In our case, the patient was subjected to suboptimal cytoreductive surgery but achieved 
a clinical benefit. After that, the patient at first begun a combination of chemotherapy 
consisting of paclitaxel and carboplatin in a weekly schedule because of the regular 
general condition. She tolerated the therapy well and presented with a marked decrease in 
serum levels of CA 125. This is the first case reported according to our knowledge in 
which the schedule of chemotherapy is performed weekly and with this combination of 
drugs. It is relevant to bear these results in mind because this schedule might be an 
alternative to combination of cisplatin and ifosfamide, which are more toxic drugs. 
In summary, we report on a primary peritoneum neoplasm, exhibiting both 
carcinomatous and sarcomatous features, in a young woman without known risk factors 
who experienced a marked clinical benefit after cytoreductive surgery with a maximal 
effort and chemotherapy with a well-tolerated schedule. 
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Fig. 1. Microphotograph-mixture of carcinomatous and chondromatous sacromatous components. 
 
 
 
Fig. 2. Microphotograph showing chondromatous sacromatous component. 
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Fig. 3. Immunohistochemical studies showing immunoreactivity for cytokeratin AE1 in epithelial 
component whereas the coexisting sacromatous component was negative. 
 
 
 
Fig. 4. Immunohistochemical studies demonstrate immunoreactivity for smooth muscle actin (SMA). 
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